Abstract

528 Background: To evaluate the role of LHRHa-induced ovarian suppression in preserving the ovarian function (OF) during chemotherapy (CT), a phase III trial was carried out. Methods: Main eligibility criteria: stage I-III premenopausal BC patients (pts), age 18 to 45; hormone receptor (HR) status positive or negative. Arm A: CT alone; arm B: CT + T. T (supplied by Ipsen, Italy) was given every 4 wks during all CT cycles. Allowed CT regimens: CEF or EC (cyclophosphamide, epirubicin, fluorouracil); A (doxorubicin) C; CEF or EC followed by paclitaxel or docetaxel; A or E followed by CMF; CMF. Pts with HR+ tumor received tamoxifen after CT. Primary endpoint: incidence of early menopause (defined by postmenopausal levels of both FSH and estradiol [E2] and no menstrual activity) 1 yr after the end of CT. Study design: multicenter, open-label, randomized, phase III trial. Assuming an incidence of permanent menopause of 60%, for alpha = 0.05 (2-sided) and beta = 0.1 (90% power), 140 pts per arm were needed to detect a 20% absolute reduction in CT+T arm. Results: From Oct 2003 to Jan 2008, 281 pts were randomized: 133 in arm A and 148 in arm B. In both arms median age was 39 and median number of CT cycles was 6. Median cumulative dose of C was 3,840 mg (0-6,930) in arm A and 3,940 mg (0-7,200) in arm B. One yr after CT, early menopause was observed in 43 pts (32.3%; 95% CI 25-41) in arm A and in 20 pts (13.5%; 95% CI 80-91) in arm B (p = 0.0002), with a 19% absolute reduction (95% CI 8-29). Resumption of menstrual activity and/or premenopausal E2 levels was observed in 77 pts (58%; 95% CI 49-66) in arm A and in 114 pts (77%; 95% CI 69-83) in arm B (p = 0.006). Logistic regression analysis confirmed that treatment with T was independently associate with a higher probability of OF preservation (p = 0.001). Conclusions: Temporary ovarian suppression with T during CT is associated with a significant increase in OF preservation in BC pts. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Ipsen

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call